LINKER-MM4
Phase 1/2 Study of Linvoseltamab (Anti-BCMA X Anti-CD3 Bispecific Antibody) in Previously Untreated Patients With Symptomatic Multiple Myeloma
What will happen during the trial?
The primary objectives of the study are:
For Phase 1
- To find out if linvoseltamab is safe and well tolerated
- To find out what the most appropriate dosing schedule would be for future clinical trials
For Phase 2
- To find out if it works to treat multiple myeloma
The secondary objectives of the study are:
For Phase 1 and 2
- To find out how linvoseltamab moves throughout the body over time (pharmacokinetics)
- To find out how much B-cell maturation antigen (BCMA) participants have in their blood
- To find out if the participants' immune systems respond to linvoseltamab.
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 1/2
- Enrollment
- 132 patients (estimated)
- Sponsors
- Regeneron Pharmaceuticals
- Tags
- Bispecific Antibody, B-Cell Maturation Antigen (BCMA), CD3
- Trial Type
- Treatment
- Last Update
- 2 weeks ago
- SparkCures ID
- 1479
- NCT Identifier
- NCT05828511
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.